Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.68 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161150 | 0.87 | OPRM1 (0.66) | OPRM1OPRD1OPRK1OPRL1SLC22A1 | |
| SCHEMBL19475380 | 0.86 | OPRM1 (0.66) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| SCHEMBL11685046 | 0.84 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| SCHEMBL11684188 | 0.83 | OPRM1 (0.63) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| SCHEMBL10607282 | 0.83 | OPRM1 (0.61) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL19717859 | 0.82 | OPRL1 (0.61) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL11682701 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| Hydrochloric Acid SCHEMBL28339752 | 0.81 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1SLC22A1 | |
| SCHEMBL3018551 | 0.79 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| SCHEMBL7848116 | 0.79 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260007323-A1 | NEUROMELANIN-SENSITIVE MRI FOR ASSESSING PARKINSON'S DISEASE | TERRAN BIOSCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250262218-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | Auros Pharma LLC | 2025-08-21 | — | — | US | disclosed |
| WO-2025123013-A1 | COMPOSITIONS FOR TREATING ADDICTION, DEPENDENCE, WITHDRAWAL, AND/OR OPIOID INDUCED HYPERALGESIA | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250066085-A1 | CANNABINOID AND ALKALOID BEVERAGE CONTAINERS, AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS | Green Sky Creations LLC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-0819002-B1 | USE OF IMIDAZO-[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON TRADING & INVESTIMEN (PT) | 2002-08-28 | — | — | EP | disclosed |
| US-5891891-A | PARKINSON'S DISEASE, NERVOUD SYSTEM DISORDERS AND DEMENTIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1999-04-06 | — | — | US | disclosed |
| EP-0819002-A1 | USE OF IMIDAZOL 1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | Clarendon-Trading & Investimentos LDA (PT) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031210-A1 | USE OF IMIDAZO[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA | CLARENDON-TRADING & INVESTIMENTOS LDA (PT) | 1996-10-10 | — | — | WO | disclosed |
| EP-0207011-B1 | USE OF SOME ALKANOYL L-CARNITINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THERAPEUTICAL TREATMENT OF IDIOPATHIC AND INDUCED PARKINSONISM | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-08-26 | — | — | EP | disclosed |
| US-4663352-A | Use of some alkanoyl L-carnitines for the therapeutical treatment of idiopathic and induced Parkinsonism | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1987-05-05 | — | — | US | disclosed |
| EP-0207011-A2 | Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | OPRM1 6/4885OPRD1 4/4885OPRK1 7/4885 |
| US-20260007323-A1 | NEUROMELANIN-SENSITIVE MRI FOR ASSESSING PARKINSON'S DISEASE | SNCA, PARK7, NMBR | OPRM1 204/4885OPRD1 430/4885OPRK1 556/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | OPRM1 3/4885OPRD1 11/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.